Effects of early human recombinant erythropoietin therapy on the transfusion in healthy preterm infants

Khatami, Seyedeh Fatemeh; Mamouri, Gholamali; Torkaman, Mohamad

doi:10.1007/s12098-008-0225-0

Cited by 11 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As high hemoglobin level and absence of anaemia has a profound role on tissue oxygenation, cellular growth and proliferation as well as metabolic function, so an increment of weight was found from enrolment to the 12 th week follow upin oral and S/C group respectively. This finding is consistent with a study done by Khatami et al 26 Many controversial questions regarding the use of rhEPO in attempts to either diminish the severity of or to treat AOP, still remain unanswered. Strauss stated that rhEPO has efficiency in stimulating erythropoiesis in preterm infants, but the success in elimination or marked reduction in the need for RBC transfusion has not been definitively demonstrated.…”

Section: Discussionsupporting

confidence: 92%

See 1 more Smart Citation

Effect of Oral Erythropoietin in Prevention of Anemia of Prematurity

Alam¹,

Khan

Nahar

et al. 2018

Bangladesh J Child Health

View full text Add to dashboard Cite

Introduction: Anemia of prematurity (AOP) is a common problem of very low birth weight babies. Blood transfusion is a necessity when it occurs in moderate to Methods: This randomized controlled study conducted in the NICU of BSMMU over one year. Total 60 preterm (<34 weeks)VLBW (<1500g) infants were enrolled and randomly divided into Control (group-I), Oral (group-II) and Subcutaneous (group III). Experimental groups (group-II & group-III) received rhEPO 400 IU/Kg, 3 times weekly in oral and subcutaneous (S/C) route respectively and continued for 2 weeks (Total 6 doses). Therapy was initiated 14 days after birth when the baby achieved oral feeding of at least 50 ml/kg/day of breast milk. All infants received oral iron and folic acid

show abstract

Section: Discussionsupporting

confidence: 92%

“…26 A multi centric European study in VLBW infants showed no benefit in the first two weeks after birth. 27 These findings are consistent with our study, where intervention and hematologic evaluation was done after two weeks of post natal age.…”

Section: Discussionmentioning

confidence: 99%

Effect of Oral Erythropoietin in Prevention of Anemia of Prematurity

Alam¹,

Khan

Nahar

et al. 2018

Bangladesh J Child Health

View full text Add to dashboard Cite

show abstract

“…Several of these clinical trials have been summarized in Table 1.5. Primary outcomes for Epo clinical trials include the use of one or more RBC transfusion (3)(4)(5)(6)(7)(109)(110)(111)(112)(113)(114)(115)(116)(117), the total volume (mL/kg) of blood transfused per infant (6,112,113,117), the number of RBC transfusions per infant (3,5,(112)(113)(114)(115)(116)(117)(118)(119)(120), the number of donors the infant was exposed to (3,120), infant mortality during initial hospital stay (3,4,6,7,109,111,118,119) and length of hospital stay (113,119,121). In addition, the main side effects analyzed for Epo clinical trials include retinopathy of prematurity (3,7,111,1...…”

Section: Epo Clinical Trials Conducted In Preterm Infantsmentioning

confidence: 99%

Optimization of anemia management in preterm infants

Rosebraugh¹

View full text Add to dashboard Cite

Premature infants develop anemia in their first few weeks of life. This is the result of heavy laboratory blood loss, shortened red blood cell lifespan, low plasma erythropoietin levels and inadequate erythropoiesis. As treatment for clinically significant anemia, approximately 80% of very low birth weight infants weighing less than 1.5kg at birth and 95% of extremely low birth weight infants weighing less than 1.0kg at birth receive one or more red blood cell transfusions. To reduce or eliminate red blood cell transfusions is important because they are expensive and associated with complications including infection, fluid overload, electrolyte imbalance, transfusion related acute lung injury and exposure to plasticizers, lead, and other toxins.The primary objective of this thesis is to examine erythropoietin (Epo) dosing, laboratory phlebotomy reduction and the use of restrictive red blood cell transfusion criteria to determine the potential to reduce or eliminate the need for red blood cell transfusions in preterm infants. In order to accomplish this objective, data were obtained from 27 preterm infants including: erythropoietin concentrations, phlebotomy volumes, transfusion information and multiple hematologic indices. The data were analyzed and modeled according to pharmacokinetic and pharmacodynamic principles to determine, through simulation studies, the potential for avoiding blood transfusions in preterm infants. Results from this research suggests that Epo administration, phlebotomy reductions and the use of restrictive blood transfusion criteria all have the potential to reduce the need for blood transfusions in preterm infants. Specifically, a combination of the three interventions was predicted to make blood transfusions unnecessary in all infants with a birth weight between 1.0-1.5kg, and 45% of infants with a birth weight of Abstract Approved: ____________________________________ Thesis Supervisor ____________________________________

show abstract